Prozac Research Today is a free monthly online journal that collates and summarizes the latest research about Prozac, including details on depression, side-effects, withdrawal, alternatives.

Case history: the discovery of fluoxetine hydrochloride (Prozac).

Wong DT, Perry KW, Bymaster FP

Department of Psychiatry, Indiana University School of Medicine, Indianapolis 46202, USA. dtwongindy@iquest.net

In the early 1970s, evidence of the role of serotonin (5-hydroxytryptamine or 5-HT) in depression began to emerge and the hypothesis that enhancing 5-HT neurotransmission would be a viable mechanism to mediate antidepressant response was put forward. On the basis of this hypothesis, efforts to develop agents that inhibit the uptake of 5-HT from the synaptic cleft were initiated. These studies led to the discovery and development of the selective serotonin-reuptake inhibitor fluoxetine hydrochloride (Prozac; Eli Lilly), which was approved for the treatment of depression by the US FDA in 1987. Here, we summarize this research and discuss the many challenges that we encountered during the development of fluoxetine hydrochloride, which has now been widely acknowledged as a breakthrough drug for depression.

Published 2 September 2005 in Nat Rev Drug Discov, 4(9): 764-74.
Full-text of this article is available online (may require subscription).

© 2004-2008 Prozac Research Today. All Rights Reserved.